Related Posts
Time to switch to bonds in your 401k?
Senior UI / UX Designer (aka Sr. Interaction Designer) wanted at Ernst & Young.
Full-time, fully remote.
Adobe XD knowledge required.
Location negotiation, *even if not listed in job post*.
Competetive salary, annual bonus, unlimited PTO, and 2 extra weeks paid holiday when firm shuts down for July 4th and Christmas. Several other great benefits.
DM me or reply below - Will provide direct referral to recruiter and hiring manager for a qualified candidate:
https://careers.ey.com/ey/job/Atlanta-Interaction-Designer%2C-Senior-Associate-Various-Locations-GA-30308/832749001/
More Posts
Advisory group? Level? Location? Salary?
Additional Posts in Life Sciences Consulting
Thoughts on bridgebio as an exit?
Anyone heard of BrightInsight company?
Are you crowdsourcing answers to interview questions?
well the bill stipulates that you would need to be in the top 50 (but in reality top 20) of spending by Part D and B drugs. Only then would you be subject to the new negotiation timeline. So depending on the drug not that big of deal. I imagine the TAs that will be impacted are the ones that have broad, older populations (T2D, CVD, Oncology, Obesity). But also just because people say this will happen does not mean it will... Politics, in the words of Kinky Friedman means multiple blood sucking animals
Am I correct in thinking companies don’t HAVE to be on the formulary? And isn’t there a selection process for Medicare only covering 2 products per indication?
IMO it won’t. I think it is 10 drugs (already approved) and those price changes aren’t going to change until 2026. And by 2029 it is 60 drugs. The number of Biological drugs (some have high prices) is about 325 at the moment, so really a small fraction even at 60. And as far as I know, no one forces companies to be on the Medicare Formulary, so they don’t have to negotiate, just means they won’t be included on the list of Medicaid approved drugs. Companies involved in R&D aren’t going to stop development because of this. If it would, then there would be no biotech/pharma in the EU as many countries do a “tender”.
Meaning a company could be the sole supplier for a govt sponsored health program for a country should they “tender” the lowest price. Or in other words cheapest bid wins.
The top 10 highest Medicare priced products are here: https://www.aarp.org/politics-society/advocacy/info-2022/medicare-prescription-drug-costs.html
I think the comments are fairly right. That’s said, I think that this will give a framework for commercial payers on how to negotiate drugs prices. I think it will impact not just the selected 10-60 drugs, but all the drugs affecting old people
No I’m generally curious.